DK1849009T3 - Anvendelse af cardiachormoner til diagnose af cardiovaskulære risici som fölge af en administration af antiinflammatoriske lægemidler - Google Patents
Anvendelse af cardiachormoner til diagnose af cardiovaskulære risici som fölge af en administration af antiinflammatoriske lægemidlerInfo
- Publication number
- DK1849009T3 DK1849009T3 DK06703569T DK06703569T DK1849009T3 DK 1849009 T3 DK1849009 T3 DK 1849009T3 DK 06703569 T DK06703569 T DK 06703569T DK 06703569 T DK06703569 T DK 06703569T DK 1849009 T3 DK1849009 T3 DK 1849009T3
- Authority
- DK
- Denmark
- Prior art keywords
- patient
- risk
- diagnosing
- administration
- cardiac
- Prior art date
Links
- 230000000747 cardiac effect Effects 0.000 title abstract 6
- 239000005556 hormone Substances 0.000 title abstract 6
- 229940088597 hormone Drugs 0.000 title abstract 6
- 230000002526 effect on cardiovascular system Effects 0.000 title abstract 4
- 229940124599 anti-inflammatory drug Drugs 0.000 title 1
- 101150071146 COX2 gene Proteins 0.000 abstract 3
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 abstract 3
- 101150000187 PTGS2 gene Proteins 0.000 abstract 3
- 108020001621 Natriuretic Peptide Proteins 0.000 abstract 2
- 102000004571 Natriuretic peptide Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000000692 natriuretic peptide Substances 0.000 abstract 2
- 102400001263 NT-proBNP Human genes 0.000 abstract 1
- 229940111134 coxibs Drugs 0.000 abstract 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/041,671 US20060166303A1 (en) | 2005-01-24 | 2005-01-24 | Use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs |
| EP05003114A EP1691200A1 (fr) | 2005-02-14 | 2005-02-14 | L'utilisation des peptides de type BNP et ANP pour évaluer les risques des complications cardiovasculaires dues a une surcharge de volume |
| US11/297,923 US7432107B2 (en) | 2005-01-24 | 2005-12-08 | Cardiac hormones for assessing cardiovascular risk |
| PCT/EP2006/050417 WO2006077265A1 (fr) | 2005-01-24 | 2006-01-24 | Utilisation de peptides de type bnp et de type anp pour evaluer le risque d'etre atteint d'une complication cardiovasculaire suite a une surcharge de volume |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1849009T3 true DK1849009T3 (da) | 2009-01-12 |
Family
ID=35892566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06703569T DK1849009T3 (da) | 2005-01-24 | 2006-01-24 | Anvendelse af cardiachormoner til diagnose af cardiovaskulære risici som fölge af en administration af antiinflammatoriske lægemidler |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP1986012B1 (fr) |
| JP (1) | JP4870686B2 (fr) |
| AT (1) | ATE412910T1 (fr) |
| CA (1) | CA2595794A1 (fr) |
| DE (1) | DE602006003411D1 (fr) |
| DK (1) | DK1849009T3 (fr) |
| ES (2) | ES2388795T3 (fr) |
| PT (1) | PT1849009E (fr) |
| WO (1) | WO2006077265A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2336359E (pt) | 2002-05-09 | 2016-06-03 | The Brigham And Women`S Hospital Inc | 1l1rl-1 como um marcador de doença cardiovascular |
| EP2848938B1 (fr) | 2006-04-24 | 2017-08-02 | Critical Care Diagnostics, Inc. | L'évaluation de l'efficacité d'un traitement d'un sujet en fonction des niveaux de ST2 |
| ES2380711T3 (es) | 2006-05-01 | 2012-05-17 | Critical Care Diagnostics, Inc. | Diagnóstico de enfermedades cardiovasculares |
| EP2103943A1 (fr) | 2008-03-20 | 2009-09-23 | F. Hoffman-la Roche AG | GDF-15 pour évaluer un risque cardiovasculaire en respectant l'administration des médicaments anti-inflammatoires |
| PL2827152T3 (pl) | 2008-04-18 | 2016-12-30 | Rokowanie ryzyka głównych niekorzystnych zdarzeń sercowych | |
| EP2133696A1 (fr) | 2008-06-10 | 2009-12-16 | Eberhardt Spanuth | Concentrations très faibles de troponine I ou T pour évaluer un risque cardiovasculaire en fonction de l'administration de médicaments anti-inflammatoires |
| ES2644723T3 (es) * | 2008-07-23 | 2017-11-30 | F. Hoffmann-La Roche Ag | Identificación de sujetos susceptibles de tratamiento antiangiogénico |
| EP2467719A4 (fr) * | 2009-08-19 | 2013-01-09 | Détection par marqueur pour caractériser le risque de maladie cardiovasculaire ou de complications associées | |
| EP3485908B1 (fr) | 2009-10-16 | 2021-08-18 | Mereo BioPharma 5, Inc. | Combinaison thérapeutique et utilisation d'anticorps antagonistes de dll4 et d'agents anti-hypertenseurs |
| JP6170496B2 (ja) | 2011-09-23 | 2017-07-26 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用 |
| CA3081979C (fr) | 2011-12-01 | 2023-07-11 | F. Hoffmann-La Roche Ag | Nt-proanp et nt-probnp pour le diagnostic d'accident vasculaire cerebral |
| AU2013305829A1 (en) | 2012-08-21 | 2015-03-05 | Critical Care Diagnostics, Inc. | Multimarker risk stratification |
| WO2014071018A1 (fr) * | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Méthodes et surveillance d'un traitement par un antagoniste de dll4 |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| JP7075611B1 (ja) * | 2021-10-28 | 2022-05-26 | 国立大学法人 東京大学 | 情報処理装置、プログラム及び情報処理方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US7632647B2 (en) * | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
| CA2414073A1 (fr) | 2001-05-04 | 2002-11-14 | Gunars E. Valkirs | Marqueurs diagnostiques de syndromes coronaires aigus et leurs methodes d'utilisation |
| JP4610025B2 (ja) * | 2002-11-18 | 2011-01-12 | シン．クス ファーマ、インコーポレイテッド | ＮＴ−ｐｒｏＢＮＰ検出用ポリクローナル・モノクローナル・エライサ検定法 |
| ES2311895T3 (es) | 2004-03-15 | 2009-02-16 | F. Hoffmann-La Roche Ag | El uso de los peptidos tipo bnp y de los peptidos tipo anf para evaluar el riesgo de padecer una complicacion cardio-vascular como frecuencia de sobrecarga del volumen. |
-
2006
- 2006-01-24 JP JP2007551689A patent/JP4870686B2/ja active Active
- 2006-01-24 CA CA002595794A patent/CA2595794A1/fr not_active Abandoned
- 2006-01-24 DK DK06703569T patent/DK1849009T3/da active
- 2006-01-24 WO PCT/EP2006/050417 patent/WO2006077265A1/fr not_active Ceased
- 2006-01-24 AT AT06703569T patent/ATE412910T1/de active
- 2006-01-24 EP EP08162219A patent/EP1986012B1/fr active Active
- 2006-01-24 EP EP06703569A patent/EP1849009B1/fr active Active
- 2006-01-24 PT PT06703569T patent/PT1849009E/pt unknown
- 2006-01-24 DE DE602006003411T patent/DE602006003411D1/de active Active
- 2006-01-24 ES ES08162219T patent/ES2388795T3/es active Active
- 2006-01-24 ES ES06703569T patent/ES2316044T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008528958A (ja) | 2008-07-31 |
| EP1986012B1 (fr) | 2012-06-06 |
| WO2006077265A1 (fr) | 2006-07-27 |
| ATE412910T1 (de) | 2008-11-15 |
| CA2595794A1 (fr) | 2006-07-27 |
| EP1849009A1 (fr) | 2007-10-31 |
| PT1849009E (pt) | 2009-01-14 |
| DE602006003411D1 (de) | 2008-12-11 |
| EP1986012A1 (fr) | 2008-10-29 |
| ES2388795T3 (es) | 2012-10-18 |
| ES2316044T3 (es) | 2009-04-01 |
| JP4870686B2 (ja) | 2012-02-08 |
| EP1849009B1 (fr) | 2008-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1849009T3 (da) | Anvendelse af cardiachormoner til diagnose af cardiovaskulære risici som fölge af en administration af antiinflammatoriske lægemidler | |
| ATE373827T1 (de) | Kombination von markern für diabetes typ 1 und 2 | |
| Palazzuoli et al. | Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin | |
| Cummings et al. | Vertical sleeve gastrectomy improves glucose and lipid metabolism and delays diabetes onset in UCD-T2DM rats | |
| Douillard et al. | SFE/SFHTA/AFCE Consensus on Primary Aldosteronism, part 2: First diagnostic steps | |
| JP2010509575A5 (fr) | ||
| NO20071040L (no) | Fremgangsmate og anordning for maling av faseendringen foranledighet i et lyssignal | |
| RU2009139295A (ru) | Биомаркеры и биомаркерные признаки почечной сохранности, обладающие предсказательной силой, для использования в мониторинге состояния почек | |
| BRPI1008178A8 (pt) | Descarga de baterias | |
| Chen et al. | Muscle at risk: the multiple impacts of ammonia on sarcopenia and frailty in cirrhosis | |
| DE602005001299D1 (de) | Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes | |
| WO2008089994A8 (fr) | Utilisation de igfbp-7 dans l'évaluation d'une insuffisance cardiaque | |
| Kim et al. | Lower uncarboxylated osteocalcin and higher sclerostin levels are significantly associated with coronary artery disease | |
| DK1650348T3 (da) | Fremgangsmåde til aftastning af et sporunderlag | |
| BR112013031354A2 (pt) | "método de perfilar uma amostra de um indivíduo para febre hemorrágica da dengue, método de identificação de um indivíduo com risco de febre hemorrágica da dengue e kit para a identificação de um indivíduo infectado pelo vírus da dengue" | |
| Shah et al. | The association between pulmonary hypertension and stroke: a systematic review and meta-analysis | |
| Charles et al. | Urotensin II: evidence for cardiac, hepatic and renal production | |
| Clerico et al. | New issues on measurement of B-type natriuretic peptides | |
| Sun et al. | Measurement of a MMP-2 degraded Titin fragment in serum reflects changes in muscle turnover induced by atrophy | |
| Le Goff et al. | Intense sport practices and cardiac biomarkers | |
| MX2012002797A (es) | Panel multimarcador para hipertrofia ventricular izquierda. | |
| ATE426675T1 (de) | Differenzialdiagnostik mit hepcidin | |
| WO2010043393A8 (fr) | Utilisation de biglycane dans l’évaluation d’une insuffisance cardiaque | |
| DK2274623T3 (da) | Fremgangsmåde til diagnosticering af pulmonal arteriel hypertension | |
| Broch et al. | Exercise capacity and peak oxygen consumption in asymptomatic patients with chronic aortic regurgitation |